Raul G. Carlini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Raul G. Carlini has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
Ezequiel Bellorin-Font
5 shared publicationsJosé R. Weisinger
4 shared publicationsEudocia Rojas
3 shared publicationsMarcos Rothstein
3 shared publicationsEddy Hernández
Division of Nephrology, Hospital Universitario de Caracas, Universidad Central de Venezuela, Caracas, Venezuela
2 shared publications- Ezequiel Bellorin-Font
National Center of Dialysis and Transplantation, Ministry of Health and the Division of Nephrology, Hospital Universitario de Caracas, Caracas, Venezuela
2 shared publications
Latest Publications
- 4 February 2021
- Published by Springer Nature in Nature Reviews Nephrology
- Vol. 17 (8) , 507-508
Kidney disease in Venezuela: the impact of a lingering humanitarian crisis
Venezuela is going through a humanitarian crisis that has severely impacted all programmes of kidney replacement therapy — dialysis coverage has decreased markedly, particularly in small towns and rural areas, and almost all peritoneal dialysis and deceased donor organ procurement for kidney transplantation have been discontinued.
- 4 February 2021
- Published by Springer Nature in Nature Reviews Nephrology
- Vol. 17 (8) , 507-508
Kidney disease in Venezuela: the impact of a lingering humanitarian crisis
Venezuela is going through a humanitarian crisis that has severely impacted all programmes of kidney replacement therapy — dialysis coverage has decreased markedly, particularly in small towns and rural areas, and almost all peritoneal dialysis and deceased donor organ procurement for kidney transplantation have been discontinued.
- 12 December 2013
- Vol. 34 (34) , 96-104
The First Report of The Latin American Society of Nephrology and Hypertension (SLANH) Anemia Committee in Chronic Hemodialysis Patients
Anemia almost invariably occurs in patients with chronic kidney disease. Limited data are available regarding anemia management in Latin American (LA) hemodialysis (HD) patients. To evaluate the results of the first anemia survey of the Anemia Committee of the SLANH. This is a multinational, voluntary survey that collected anemia management data from adult HD patients from independent, non-chain owned HD units, between 09/2009 and 03/2010. T-test, ANOVA, chi-square test and multivariate logistic regression were used for statistical analysis. The survey received responses from 134 HD units of 16 countries providing data from 9,025 patients. Mean values of Hb, ferritin, and transferrin saturation (TSAT) were 10.5 ± 1.8 g/dL, 570 ± 539 µg/l, and 29.8 ± 15%, respectively. Only 32.7% of patients were within the Hb target of 10.5-12.0 g/dL (46.3% were below and 21.1% above). Erythropoietin-stimulating agents (ESAs) were administered to 84.3% patients and 68.3% received intravenous iron (IV). Iron deficiency (TSAT≤20%) was present in 27.5% patients and among those receiving erythropoietin, 47% did not achieve Hb target. The independent variables associated with the lowest Hb level (<10.5 g/dL) were: female gender, TSAT<25% and age<50 years. According to these results, nearly half of LA chronic HD patients did not achieve the recommended Hb target despite wide use of ESAs and IV iron.
- 12 December 2013
- Vol. 34 (34) , 96-104
The First Report of The Latin American Society of Nephrology and Hypertension (SLANH) Anemia Committee in Chronic Hemodialysis Patients
Anemia almost invariably occurs in patients with chronic kidney disease. Limited data are available regarding anemia management in Latin American (LA) hemodialysis (HD) patients. To evaluate the results of the first anemia survey of the Anemia Committee of the SLANH. This is a multinational, voluntary survey that collected anemia management data from adult HD patients from independent, non-chain owned HD units, between 09/2009 and 03/2010. T-test, ANOVA, chi-square test and multivariate logistic regression were used for statistical analysis. The survey received responses from 134 HD units of 16 countries providing data from 9,025 patients. Mean values of Hb, ferritin, and transferrin saturation (TSAT) were 10.5 ± 1.8 g/dL, 570 ± 539 µg/l, and 29.8 ± 15%, respectively. Only 32.7% of patients were within the Hb target of 10.5-12.0 g/dL (46.3% were below and 21.1% above). Erythropoietin-stimulating agents (ESAs) were administered to 84.3% patients and 68.3% received intravenous iron (IV). Iron deficiency (TSAT≤20%) was present in 27.5% patients and among those receiving erythropoietin, 47% did not achieve Hb target. The independent variables associated with the lowest Hb level (<10.5 g/dL) were: female gender, TSAT<25% and age<50 years. According to these results, nearly half of LA chronic HD patients did not achieve the recommended Hb target despite wide use of ESAs and IV iron.
- 1 October 2013
- Published by Elsevier in The Lancet
- Vol. 382 (9900) , 1244
Global kidney disease.
- 1 April 2013
- No. 33 Suppl,p. 1-28
Guías de práctica clínica para la prevención, diagnóstico, evaluación y tratamiento de los trastornos minerales y óseos en la enfermedad renal crónica (TMO-ERC) en adultos
The clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of chronic kidney disease mineral and bone disorders (CKD-BMD) in adults, of the Latin American Society of Nephrology and Hypertension (SLANH) comprise a set of recommendations developed to support the doctor in the management of these abnormalities in adult patients with stages 3-5 kidney disease. This excludes changes associated with renal transplantation. The topics covered in the guidelines are divided into four chapters: 1) Evaluation of biochemical changes, 2) Evaluation of bone changes, 3) Evaluation of vascular calcifications, and 4) Treatment of CKD-MBD. The guidelines are based on the recommendations proposed and published by the Kidney Disease: Improving Global Outcomes (KDIGO) for the prevention, diagnosis, evaluation and treatment of CKD-MBD (KDIGO Clinical practice guidelines for the diagnosis, evaluation, prevention and treatment of Chronic Kidney Disease Mineral and Bone Disorder [CKD-MBD]), adapted to the conditions of patients, institutions and resources available in Latin America, with the support of KDIGO. In some cases, the guidelines correspond to management recommendations directly defined by the working group for their implementation in our region, based on the evidence available in the literature. Each chapter contains guidelines and their rationale, supported by numerous updated references. Unfortunately, there are few controlled studies with statistically sufficient weight in Latin America to support specific recommendations for the region, and as such, most of the references used correspond to studies carried out in other regions. This highlights the need to plan research studies designed to establish the current status of mineral and bone metabolism disorders in Latin America as well as defining the best treatment options for our population.
- 1 April 2013
- No. 33 Suppl,p. 1-28
Guías de práctica clínica para la prevención, diagnóstico, evaluación y tratamiento de los trastornos minerales y óseos en la enfermedad renal crónica (TMO-ERC) en adultos
The clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of chronic kidney disease mineral and bone disorders (CKD-BMD) in adults, of the Latin American Society of Nephrology and Hypertension (SLANH) comprise a set of recommendations developed to support the doctor in the management of these abnormalities in adult patients with stages 3-5 kidney disease. This excludes changes associated with renal transplantation. The topics covered in the guidelines are divided into four chapters: 1) Evaluation of biochemical changes, 2) Evaluation of bone changes, 3) Evaluation of vascular calcifications, and 4) Treatment of CKD-MBD. The guidelines are based on the recommendations proposed and published by the Kidney Disease: Improving Global Outcomes (KDIGO) for the prevention, diagnosis, evaluation and treatment of CKD-MBD (KDIGO Clinical practice guidelines for the diagnosis, evaluation, prevention and treatment of Chronic Kidney Disease Mineral and Bone Disorder [CKD-MBD]), adapted to the conditions of patients, institutions and resources available in Latin America, with the support of KDIGO. In some cases, the guidelines correspond to management recommendations directly defined by the working group for their implementation in our region, based on the evidence available in the literature. Each chapter contains guidelines and their rationale, supported by numerous updated references. Unfortunately, there are few controlled studies with statistically sufficient weight in Latin America to support specific recommendations for the region, and as such, most of the references used correspond to studies carried out in other regions. This highlights the need to plan research studies designed to establish the current status of mineral and bone metabolism disorders in Latin America as well as defining the best treatment options for our population.
- 1 August 2005
- Published by Elsevier in Kidney International
- Vol. 68 (97) , S18-S22
Access to and coverage of renal replacement therapy in minorities and ethnic groups in Venezuela
- 1 August 2005
- Published by Elsevier in Kidney International
- Vol. 68 (97) , S18-S22
Access to and coverage of renal replacement therapy in minorities and ethnic groups in Venezuela
- 1 June 2003
- Published by Elsevier in Kidney International
- Vol. 63 (85) , S125-S128
Bone remodeling after renal transplantation
- 1 June 2003
- Published by Elsevier in Kidney International
- Vol. 63 (85) , S125-S128
Bone remodeling after renal transplantation
- 1 June 2003
- Published by Elsevier in Kidney International
- Vol. 63 (6) , 2269-2274
Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis
- 1 June 2003
- Published by Elsevier in Kidney International
- Vol. 63 (6) , 2269-2274
Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis
- 1 June 2003
- Published by Elsevier in Kidney International
- Vol. 63 (85) , S62-S65
Selective estrogen receptor modulators in chronic renal failure
- 1 June 2003
- Published by Elsevier in Kidney International
- Vol. 63 (85) , S62-S65
Selective estrogen receptor modulators in chronic renal failure
- 1 May 2003
- Published by Elsevier in Kidney International
- Vol. 63 (5) , 1915-1923
The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling
- 1 May 2003
- Published by Elsevier in Kidney International
- Vol. 63 (5) , 1915-1923
The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling
- 1 July 2000
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 36 (1) , 160-166
Bone disease in patients with long-term renal transplantation and normal renal function
- 1 July 2000
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 36 (1) , 160-166
Bone disease in patients with long-term renal transplantation and normal renal function